Background: The BRAF V600E mutation status is a useful diagnostic and prognostic
aim of this study was to evaluate the efficiency of droplet digital PCR (ddPCR) as an alternative method for the detection of the BRAF V600E mutation in PTC patients.
Methods:
Samples from a total of 120 patients with PTC and 30 patients with benign nodular thyroid disease who underwent thyroid surgery were collected. The BRAF V600E mutation status of the PTC patients was tested by Sanger sequencing and ddPCR.
Results:
The BRAF V600E mutation was detected in 67 samples (44.67%) by Sanger sequencing and 92 samples (61.33%) by ddPCR. The detection of the mutation by the two methods was inconsistent in twenty-five samples (16.67%). The sensitivity and specificity of the ddPCR method were 100% and 69.88%, respectively, and the positive predictive and negative predictive values were 72.83% and 100%, respectively.
The concordance rate between the two methods in detecting the BRAF V600E mutation was 83.33%. Neither Sanger sequencing nor ddPCR detected BRAF V600E in 30 patients with benign nodular thyroid disease. The 92 samples with the BRAF V600E mutation were detected by ddPCR at a fractional abundance from 0.28% to 45.40%
as follows: ≥10% (59 samples, 64.13%), 5%-10% (8 samples, 8.70%), and ≤5% (25 samples, 27.17%). The BRAF V600E mutation was detected in all 59 samples at a fractional abundance ≥10% and in four samples at a fractional abundance from 5% to 10%, and no BRAF V600E mutation was detected at a fractional abundance ≤5% by Sanger sequencing.
Conclusions: ddPCR was a reliable, highly sensitive alternative method for the detection of the BRAF V600E mutation in PTC patients.
K E Y W O R D S
BRAF V600E mutation, ddPCR, papillary thyroid carcinoma, Sanger sequencing The limit of detection of ddPCR is 0.0005%. 11 Therefore, ddPCR analysis sensitively detects and quantifies low-abundance gene mutations like the BRAF V600E mutation.
| INTRODUC TI ON
In the present study, the BRAF V600E mutation was detected by ddPCR and Sanger sequencing. ddPCR was a better method than Sanger sequencing in detecting the BRAF V600E mutation in PTC samples.
| MATERIAL S AND ME THODS

| Patients
A total of 150 patients who underwent thyroid surgery between November 2016 and February 2019 in the Jiangsu Cancer Hospital were included in this study. All specimens were obtained after thyroid surgery, fixed in formalin, and embedded in paraffin. These samples were from 120 patients with PTC and 30 patients with benign nodular thyroid disease.
Tumor staging was performed according to the seventh edition of the tumor-node-metastasis (TNM) classification by the American Joint Committee on Cancer (8th edition). All patients who participated in the study gave their informed consent.
| DNA extraction
Hematoxylin-eosin slides prepared from specimens were examined by two experienced pathologists to estimate the areas enriched in tumor cell populations. Tissue was scraped from this preselected area and transferred to an Eppendorf tube for DNA extraction using the QIAamp FFPE Tissue Kit (Qiagen). Using the forward primer 5′-CTCTTCATAATGCTTGCTCTGATAGG-3′
Characteristics
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and the reverse primer 5′-AGTTGAGACCTTCAATGACTTTCTAGT-3′, exon 15 of the BRAF gene, which potentially contained the T1799A transversion mutation (encoding BRAF V600E ), was amplified by PCR.
Amplification was performed under the following conditions: 1 cycle at 95°C for 5 minutes, 35 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 40 seconds; followed by a final extension at 72°C for 5 minutes using
Premix Taq™ Hot Start Version (Takara). The purified PCR products were sequenced using the forward primer above and a BigDye
Terminator v 3.1 kit (Thermo Fisher). Capillary separation and data collection were performed on an ABI 3500 Genetic Analyzer.
| ddPCR analysis to detect the BRAF V600E mutation
The GCT-MGB-3′). Droplets were generated and analyzed using the QX200 system (Bio-Rad). Amplification was performed as follows:
95°C for 10 minutes (1 cycle), 94°C for 30 seconds and 55°C for 1 minutes (40 cycles), and 98°C for 10 minutes (1 cycle) with a ramp rate of 2°C/s, and the reaction was then held at 4°C with a ramp rate of 1°C/s. The absolute quantification of mutant alleles and wild-type alleles by ddPCR was estimated by modeling as a Poisson distribution using QuantaSoft v1.6.6 analysis software (Bio-Rad). The threshold was defined as that described in the "Droplet Digital Application Guide." Samples with a droplet number of more than 3 in the positive area were considered positive by the QuantaSoft analysis software.
| RE SULTS
| Clinical characteristics
The clinical characteristics of the patients are shown in Table 1 .
Of the included patients, 62 (41.33%) were male and 88 (58.67%)
were female, and the average age was 57 years (ranged from 17 to 72). 
| Comparison of Sanger sequencing and ddPCR detection of the BRAF V600E mutation
| Fractional abundance of PTC patients with BRAF V600E mutation
A total of 92 samples with the BRAF V600E mutation were detected by ddPCR at a fractional abundance from 0.28% to 45.40%. Of these, 59 samples (64.13%) were detected at a fractional abundance ≥10%, 8 samples (8.70%) were detected at a fractional abundance from 5%
to 10%, and 25 samples (27.17%) were detected at a fractional abundance ≤5% (Table 4) .
Among the 92 positive samples detected by ddPCR, the BRAF V600E mutation was detected in all 59 samples at a fractional abundance ≥10% and in four samples at a fractional abundance from 5% to 10% by Sanger sequencing. Twenty-five samples were detected at a fractional abundance ≤5% by ddPCR, but Sanger sequencing indicated wild-type BRAF in these samples.
| D ISCUSS I ON
The BRAF V600E mutation is the most common driver mutation in PTC and acts as a useful diagnostic and prognostic marker for PTC.
12-14
Sanger sequencing is the gold standard for detecting the BRAF V600E mutation and is a commonly used method in laboratories.
Because of its relatively low sensitivity, the detection of mutations requires a large amount of tumor DNA in the samples. ddPCR is a relatively new method with multiple advantages, such as improved sensitivity and absolute quantification. Table 5 .
The BRAF V600E mutation was found in 55.83% of PTC patients by Sanger sequencing and 76.67% by ddPCR in the present study.
A higher mutation rate was detected by ddPCR. These results were consistent with previous studies that showed a BRAF V600E mutation rate of 29%-90%. 2, 14, 20, 21 In the present study, the BRAF V600E mutation was only detected in PTC patients and not in patients with benign nodular thyroid disease, which was also consistent with previous studies.
22,23
It is important to note that mutations at a fractional abundance ≥10% would have been reported as positive by Sanger sequencing in a clinical setting. Mutations at a fractional abundance from 5% to 10% are difficult to report and would have required confirmation by another method. Mutations at a fractional abundance ≤5% cannot be detected by Sanger sequencing. In this research, good concordance was found between ddPCR and Sanger sequencing in mutations at a high fractional abundance, and all discordant results were found in mutations at a low fractional abundance, which could be explained by the greater sensitivity of ddPCR than Sanger sequencing.
Hence, it is possible that Sanger sequencing produced false-negative results because of the low tumor DNA content and low-abundance DNA mutations.
In the present study, all specimens were obtained after thyroid surgery, fixed in formalin, and embedded in paraffin. However, highquality PTC samples cannot always be acquired in a clinical setting. 
